A comprehensive review on lipid nanocarrier systems for cancer treatment : fabrication, future prospects and clinical trials
Over the last few decades, cancer has been considered a clinical challenge, being among the leading causes of mortality all over the world. Although many treatment approaches have been developed for cancer, chemotherapy is still the most utilized in the clinical setting. However, the available chemotherapeutics-based treatments have several caveats including their lack of specificity, adverse effects as well as cancer relapse and metastasis which mainly explains the low survival rate of patients. Lipid nanoparticles (LNPs) have been utilized as promising nanocarrier systems for chemotherapeutics to overcome the challenges of the currently applied therapeutic strategies for cancer treatment. Loading chemotherapeutic agent(s) into LNPs improves drug delivery at different aspects including specific targeting of tumours, and enhancing the bioavailability of drugs at the tumour site through selective release of their payload, thus reducing their undesired side effects on healthy cells. This review article delineates an overview of the clinical challenges in many cancer treatments as well as depicts the role of LNPs in achieving optimal therapeutic outcomes. Moreover, the review contains a comprehensive description of the many LNPs categories used as nanocarriers in cancer treatment to date, as well as the potential of LNPs for future applications in other areas of medicine and research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of liposome research - 34(2024), 1 vom: 02. März, Seite 135-177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kabil, Mohamed Fawzi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/08982104.2023.2204372 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356475735 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356475735 | ||
| 003 | DE-627 | ||
| 005 | 20240301231939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/08982104.2023.2204372 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM356475735 | ||
| 035 | |a (NLM)37144339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kabil, Mohamed Fawzi |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comprehensive review on lipid nanocarrier systems for cancer treatment |b fabrication, future prospects and clinical trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Over the last few decades, cancer has been considered a clinical challenge, being among the leading causes of mortality all over the world. Although many treatment approaches have been developed for cancer, chemotherapy is still the most utilized in the clinical setting. However, the available chemotherapeutics-based treatments have several caveats including their lack of specificity, adverse effects as well as cancer relapse and metastasis which mainly explains the low survival rate of patients. Lipid nanoparticles (LNPs) have been utilized as promising nanocarrier systems for chemotherapeutics to overcome the challenges of the currently applied therapeutic strategies for cancer treatment. Loading chemotherapeutic agent(s) into LNPs improves drug delivery at different aspects including specific targeting of tumours, and enhancing the bioavailability of drugs at the tumour site through selective release of their payload, thus reducing their undesired side effects on healthy cells. This review article delineates an overview of the clinical challenges in many cancer treatments as well as depicts the role of LNPs in achieving optimal therapeutic outcomes. Moreover, the review contains a comprehensive description of the many LNPs categories used as nanocarriers in cancer treatment to date, as well as the potential of LNPs for future applications in other areas of medicine and research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Lipid nanoparticles | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a cubosomes | |
| 650 | 4 | |a emulsomes | |
| 650 | 4 | |a lipid nanocapsules | |
| 650 | 4 | |a lipid nanovesicles | |
| 650 | 4 | |a nanoemulsions | |
| 650 | 4 | |a nanostructured lipid carriers | |
| 650 | 4 | |a solid lipid nanoparticles | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Badary, Osama A |e verfasserin |4 aut | |
| 700 | 1 | |a Bier, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Mousa, Shaker A |e verfasserin |4 aut | |
| 700 | 1 | |a El-Sherbiny, Ibrahim M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of liposome research |d 1994 |g 34(2024), 1 vom: 02. März, Seite 135-177 |w (DE-627)NLM089676629 |x 1532-2394 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2024 |g number:1 |g day:02 |g month:03 |g pages:135-177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/08982104.2023.2204372 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2024 |e 1 |b 02 |c 03 |h 135-177 | ||